HAYWARD, Calif.--(BUSINESS WIRE)--Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ:IPXL) today announced it has commenced a Phase III trial of IPX066 in Parkinson’s Disease (PD) patients based on encouraging interim data collected from the Phase II study in PD patients. It also clarified the U.S. Food and Drug Administration (FDA) requirement for pediatric studies of its investigational medication IPX056.
